Given that PEGylation is a common strategy to influence the blood circulation time of a therapeutic compound, as mentioned before, many FDA-approved NMs are modified with PEG including PEGylated granulocyte colony-stimulating factor (Neulasta) for the treatment of chemotherapy-induced neutropenia, PEGylated anti-hemophilic factor VIII (Adynovate) for treatment of hemophilia A and PEGylated interferon gamma beta-1a (Plegridy) for treatment of relapsing multiple sclerosis [9]. Here, CSF3 is linked to Decreased total neutrophil count.